Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
NCT07623668
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Optic Neuritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Oculis
- Last updated on ClinicalTrials.gov
- August 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- Kahana Oculoplastic and Orbital Surgery · Livonia, MI
South Carolina · 1
- Medical University of South Carolina, Storm Eye Institute · Charleston, SC
Texas · 2
- UT Southwestern Medical Center (Ophthalmology CRU) · Dallas, TX
- Neuro-Eye Clinical Trials · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.